SINGAPORE, May 5, 2016 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F, OTCPK: ZMSPF), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that the major medical OEM based in China, which selected Zecotek's patented lutetium fine silicate (LFS) scintillation crystals for a new line of high resolution positron emission tomography (PET) medical imaging devices, has received the first order of LFS scintillation crystals. As previously announced on March 23, 2016, Zecotek Imaging Systems signed a memorandum of understanding (MOU) with the medical OEM to purchase LFS scintillation crystals. The MOU contains two conditions that when met, will lead to a contractual agreement. The first condition is the delivery and receipt of the LFS crystals by the end of April 2016, and the second is the installation of the first LFS based PET scanner in a Shanghai clinic by early summer.
"We have met the first condition of our memorandum of understanding with the major medical OEM based in China," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "The LFS scintillation crystals were delivered within the specific time frame and the OEM is now installing them in the first of a new line of high resolution PET medical imaging devices. We look forward to the delivery of first PET medical scanner in July."
Based on successful execution of the contract, the major medical OEM is projecting the installation of 200 LFS based PET scanners in hospitals and clinics across China over the next five years. For competitive reasons, the OEM has requested to remain anonymous until the contract is in effect.
As one of the world's fastest growing markets, China's medical scanning device industry represents a significant opportunity for the OEM and Zecotek. China has experienced rapid economic growth, a growing middle class and an aging population, which have placed pressure on the Chinese government to increase investment in medical diagnostic equipment. Each PET scanning device is made up of scintillation crystals, photo detectors and a read out system and costs approximately $1,000,000 to manufacture. Scintillation crystals represent approximately 45 percent of the total production cost of a PET medical scanner. It is anticipate that Zecotek's other key technologies, such as solid-state MAPD/T photo detectors and the associated electronics which make up the other 35% of the cost of a PET scanner, will be ready for full production by end of third quarter 2016.
Zecotek's patented (US patent No. 7,132,060) LFS series of scintillation crystals cover a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including Zecotek's own solid-state MAPD/T photo detector arrays. The solid-state MAPD/T photo detectors offer significant performance-cost advantages over competing photomultiplier tubes (PMT) and other solid-state, silicon based photo detectors. Its low manufacturing cost, excellent timing resolution and photon detection efficiency are key characteristics for the new configurations of high resolution PET scanners.
The LFS scintillation crystals will be supplied by the Beijing Opto-Electronics Technology Company (BOET), a subsidiary of North-China Research Institute of Electronics-Optics an industry leader in growing, cutting, polishing and large scale production of scintillation crystals grown by the Czochralski method. Zecotek's manufacturing process permits the growth of very large-diameter boules with uniform properties and without cracking (a problem with many competing scintillation materials), resulting in high element output and lower unit costs.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, 3D metal printing, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Optronics Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
SOURCE Zecotek Photonics Inc.
For further information: Zecotek Photonics Inc.: Michael Minder, T: (604) 783-8291, email@example.com